Drug information provided by: Merative, Micromedex®
Crizotinib is used to treat metastatic (cancer that has already spread) non-small cell lung cancer (NSCLC) that is caused by a defect in either a gene called anaplastic lymphoma kinase (ALK) or a gene called ROS1. Your doctor will test for the presence of this gene.
Crizotinib is also used to treat relapsed (cancer that has come back) or refractory (cancer that did not respond to treatment) systemic anaplastic large cell lymphoma (ALCL) with a defect in a gene called anaplastic lymphoma kinase (ALK).
Crizotinib is also used to treat unresectable (cancer that cannot be removed by surgery), recurrent (cancer that keeps coming back), or refractory (cancer that did not respond to treatment) inflammatory myofibroblastic tumor (IMT) with a defect in a gene called anaplastic lymphoma kinase (ALK).
Crizotinib is an antineoplastic (cancer) agent. It interferes with the growth of cancer cells, which are eventually destroyed by the body.
This medicine is available only with your doctor's prescription.
This product is available in the following dosage forms:
Portions of this document last updated: July 01, 2024
Copyright: © Merative US L.P. 1973, 2024. All rights reserved. Information is for End User's use only and may not be sold, redistributed or otherwise used for commercial purposes.
لا تُقدم Mayo Clinic الدعم للشركات أو المنتجات المُعلَّن عنها هنا. لكن تدعم العائدات الإعلانية رسالتنا غير الربحية.
تحقق من هذه الكتب الأكثر مبيعًا والعروض الخاصة على الكتب والنشرات الإخبارية من Mayo Clinic Press.
تساهم التبرّعات، وهي قابلة للخصم الضريبي، في دعم آخر التطورات في الأبحاث وطرق الرعاية لإحداث نقلة نوعية في الطب.